Spartan Bioscience

Ottawa startup awaiting regulatory approval for portable device says partnership with world-renowned U.S. research facility will help further develop its technology.
Ottawa biotech startup has raised $7.5 million in fresh funding as it looks to capitalize what it says is the continued need for "a decentralized, laboratory-quality" test kit.
Spartan filed for creditor protection and laid off two-thirds of its 90 employees after facing continued questions about the reliability of its COVID-detecting lab-in-a-box.
Local biotech firm's groundbreaking platform is used by medical researchers around the world to create 3D images of hearts, knees and other body parts.
Ottawa biotech firm says it is restructuring in the wake of a “higher-than-expected level of inconclusive results” from its rapid COVID-19 testing device.
Ottawa biotech firm predicts revenues will top $200 million this year ​– and only rise from there.
Ottawa company says it plans to begin shipping the device “immediately” to federal and provincial governments as well as commercial customers.
After facing months of delays, Ottawa biotech firm is hoping its rapid testing device is poised to clear the final hurdle before it can go to market.
Chief executive Roger Eacock says rapid COVID-19 tests are poised to make local biotech company a force on the 'international stage.'
Company says it hopes to get Health Canada’s approval to market the test “in the coming weeks.”